PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80013Oseltamivir phosphate 75mg capsules (ndc — Alvogen

Alvogen holds $284.8M across 11 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award under parent V797D70134. Competition previously drew 3 offers. Recompete timing centers on the Jun 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Alvogen

Recipient

Jun 29, 2027

PoP end

$227.7M

Obligated

325412

NAICS

6505

PSC

3 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Alvogen — $90

Contract facts

Federal

Contract number75A50325F80013

Also listed asV797D70134-75A50325F80013

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

IncumbentAlvogen

UEILJNNGDV77Y98

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVV797D70134

Place of performancePINE BROOK, NJ

Related solicitation75A50325Q00001

PoP end (current)Jun 29, 2027

Obligated$227.7M

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES… is a federal award for Aspr/Orm-Sns held by Alvogen. Estimated value $227.7M ($227.7M obligated). Current period of performance ends Jun 29, 2027. Last award drew 3 bidders. Place of performance: PINE BROOK, NJ. Related solicitation 75A50325Q00001.

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS.

Recompete timing

Public

● Expiring in 313 days

Current PoP ends Jun 29, 2027 (313 days remaining). Agencies typically plan 12–18 months ahead — at 10.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Alvogen — $284.8M obligated across 11 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$284.8M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

75A50324F63003

OSELTAMIVIR PHOSPHATE 75MG, 10 CT BLISTER (ADULT COURSE)

$74.5M

Sep 28, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50325F80013?

75A50325F80013 (Oseltamivir phosphate 75mg capsules (ndc) is a Aspr/Orm-Sns award with an estimated value of $227.7M, currently held by Alvogen. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50325F80013?

Aspr/Orm-Sns awarded 75A50325F80013 to Alvogen.

Who is the incumbent on 75A50325F80013?

Alvogen is the incumbent with $284.8M across 11 related awards in SCOUT’s public footprint. The current period of performance ends Jun 29, 2027.

When does Alvogen’s 75A50325F80013 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jul 2, 2025